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Unlike other tumor necrosis factor family members,
the cytotoxic ligand tumor necrosis factor-related apo-
ptosis-inducing ligand (TRAIL)/Apo-2L contains an un-
paired cysteine residue (Cys230) in its receptor-binding
domain. Here we show that the biological activity of
both soluble recombinant TRAIL and cell-associated,
full-length TRAIL is critically dependent on the pres-
ence of Cys230. Mutation of Cys230 to alanine or serine
strongly affected its ability to kill target cells. Binding to
its receptors was decreased by at least 200-fold, and the
stability of its trimeric structure was reduced. In recom-
binant TRAIL, Cys230 was found engaged either in inter-
chain disulfide bridge formation, resulting in poorly ac-
tive TRAIL, or in the chelation of one zinc atom per
TRAIL trimer in the active, pro-apoptotic form of
TRAIL.
Ligands and receptors of the tumor necrosis factor (TNF)1
family function to trigger cell growth, differentiation, activa-
tion, and apoptosis and are mainly implicated in the mainte-
nance and function of the immune system (1). The TNF-related
apoptosis-inducing ligand (TRAIL/Apo-2L) displays cytotoxic
activity toward a number of transformed cell lines but not
against most primary cells, suggesting that it may be a useful
anti-tumor agent (2, 3). Recent reports demonstrating that
TRAIL is able to counteract progression of human tumor xe-
nografts in a murine model support this hypothesis (4, 5).
There are several receptors for TRAIL that all belong to the
TNF receptor family. These include TRAIL-R1/DR4, TRAIL-
R2/DR5, TRAIL-R3/DcR1, and TRAIL-R4/DcR2, which display
high sequence homology in their extracellular domains and
have TRAIL as their only known ligand. Osteoprotegerin
(OPG), however, belongs to a distinct subfamily and binds to
both TRANCE/RANKL/OPGL and TRAIL. The widely expressed
TRAIL-R1 and TRAIL-R2 contain an intracellular death domain
and can signal apoptosis; the remaining receptors are believed to
function as decoys and either do not contain a functional death
domain (TRAIL-R4), have a glycolipid anchor (TRAIL-R3), or
exist in a soluble form (osteoprotegerin) (for a review on TRAIL-
Rs, see Ref. 6).
The extracellular domains of TNF receptor family members
have an elongated shape stabilized by multiple disulfide
bridges, which is reflected at the level of the primary structure
by a characteristic pattern of Cys residues (7). In contrast,
ligands are formed of anti-parallel b-sheets folding into the
so-called “jellyroll” structure, which in some cases is stabilized
by a single disulfide bridge (8, 9). TRAIL is remarkable in that
it contains an unpaired Cys residue (Cys230) at the correspond-
ing position where some other ligands have a disulfide bridge.
TRAIL, alone or in complex with TRAIL-R2, has been crystal-
lized recently by three different groups (10–12). Although
Cys230 appears to be important in the organization of the dif-
ferent structures, it has been found either (a) as a free Cys
residue, (b) involved in disulfide bridge formation with Cys230
of another monomer (and as a free Cys in the remaining mon-
omer), or (c) as a zinc chelator, together with the Cys residues
of the remaining two monomers.
In this study, we show that Cys230 is required for optimal
TRAIL activity and for stabilization of the TRAIL trimeric
structure. We confirm the presence of one zinc atom per trimer
of TRAIL, and we find that the presence of the interchain
disulfide bridge decreases its specific activity, suggesting that
Cys230 in the active TRAIL coordinates a zinc atom, rather
than forming a disulfide bridge.
EXPERIMENTAL PROCEDURES
Materials—Anti-FLAG M2 antibody and M2-agarose were pur-
chased from Sigma. Anti-HA mouse IgG1 monoclonal antibody 16B12
was from Babco (Richmond, CA). Anti-mouse IgG1 g1 chain antibodies
coupled to peroxidase were purchased from Southern Biotechnology
Associates (Birmingham, AL). Fas:Fc, CD40:Fc, TRAIL-R1:Fc, TRAIL-
R2:Fc, TRAIL-R3:Fc and TRAIL-R4:Fc were obtained form Alexis (San
Diego, CA). Thermolysin from Bacillus thermoproteolyticus (;37,500
Da) was purchased from Fluka (Buchs, Switzerland) and NaCl (Supra-
pure grade, ,0.005 parts/million zinc) from Merck.
Cells—293T cells, Jurkat T lymphoblastic leukemia and BJAB Bur-
kitt lymphoma cell lines were maintained as described previously (13).
TRAIL Expression Vectors and Expression of Recombinant TRAIL—
Bacterial FLAG-TRAIL and FLAG-BAFF expression vectors encode the
following proteins: MRGSDYKDDDDKGPGQVQLQ followed by either
aa 95–281 of hTRAIL or aa 83–285 of hBAFF (13). Mammalian expres-
sion vector for HA signal-FLAG-TRAIL, HA signal-HA-TRAIL, and
FLAG-tagged full-length TRAIL encode the following predicted mature
proteins, respectively, DYKDDDDKGPGQVQLQ followed by aa 95–281
of hTRAIL, YPYTPDYAGPGQVQ followed by aa 95–281 of TRAIL, and
MDYKDDDDKEF followed by aa 1–281 of hTRAIL. These or related
vectors have been described previously (14, 15). Site-directed mutagen-
esis of Cys230 to Ala or Ser was performed by a polymerase chain
reaction-based method and was confirmed by sequencing. Expression of
FLAG-TRAIL and FLAG-BAFF was achieved by induction in M15
pRep4 bacteria (Qiagen) for 16 h at 18 °C. Bacteria were resuspended in
TBS (10 mM Tris-HCl, pH 7.5, 140 mM NaCl) and lysed in a French
press. FLAG-TRAIL and FLAG-BAFF recovered in the soluble fraction
were affinity purified on M2-agarose, eluted with 50 mM citrate-NaOH
pH 2.7, immediately neutralized with Tris-HCl, pH 9, and the buffer
was exchanged for either TBS, PBS, or 140 mM Suprapure NaCl by
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repeated centrifugation in protein concentrators (Centrikon-10 or -30,
Amicon, Easton, TX). To study the pH sensitivity of TRAIL, bacterial
pellets corresponding to 20 ml of culture were lysed in 1 ml of a
universal pH buffer containing 30 mM each sodium citrate, sodium
borate, sodium phosphate, and sodium barbital at pH 5–9. Bacterial
lysates were centrifuged for 5 min at 10,000 3 g, and supernatants,
containing TRAIL at about 100 mg/ml, were collected. For FLAG-TRAIL
produced by transient transfection of 293T cells in serum-free Opti-
MEM medium (14), cell supernatants were concentrated 20 times in
Centrikon-10.
Cytotoxic Assays—Cytotoxic assays for soluble FLAG-TRAIL were
performed in the presence of 2 mg/ml anti-FLAG M2 as described
previously (15).
For chromium release assays using transfected 293T cells, 2 3 106
BJAB cells were labeled for 1 h at 37 °C with 50 mCi of Na2[
51Cr]O4. 10
4
labeled BJAB cells were co-cultured with the indicated ratio of trans-
fected 293T cells, in the presence or absence of 10 mg/ml TRAIL-R2:Fc or
Fas:Fc. Maximum release was obtained by lysing cells in 700 mM HCl.
Released [51Cr] was monitored after 15 h, and the percentage of specific
chromium release was calculated as follows: (measured release2 spon-
taneous release)/(maximum release 2 spontaneous release).
Receptor-binding ELISA—The binding of FLAG-TRAIL (purified or
in crude bacterial extracts) to plate-bound TNF-R1:Fc and TRAIL-
R1(R2)(R3)(R4):Fc was detected with anti-FLAG M2 antibody and sec-
ondary reagents as described previously (14).
Gel Permeation Chromatography—Purified wt and mutant TRAILs
expressed in Escherichia coli were loaded onto a Superdex-200 HR10/30
column and eluted in PBS at 0.5 ml/min with on-line monitoring at 280
nm. The identity of the eluted peaks was confirmed by Western blotting
using anti-FLAG M2. The column was calibrated with a set of standard
proteins for gel filtration (Amersham Pharmacia Biotech).
Immunoprecipitations—Soluble wt or mutated TRAIL carrying
FLAG or HA tags were co-transfected in 293T cells. After 3 days, cell
supernatants were pre-cleared with Sepharose 6B and immunoprecipi-
tated with anti-FLAG M2-agarose. Beads were washed 4 times with
PBS and analyzed by Western blotting with anti-FLAG or anti-HA
antibodies followed by peroxidase-coupled anti-mouse IgG g1 chain.
For the precipitation of TRAIL with TRAIL-R2:Fc, 15 ml of protein
A-Sepharose (Amersham Pharmacia Biotech) was mixed with 20 mg of
E. coli-produced TRAIL and 10 mg of TRAIL-R2:Fc (or CD40:Fc in the
control) in a final volume of 70 ml, for 30 min at room temperature. The
reaction was poured into an empty mini-column, washed 3 times with
200 ml of PBS, and eluted with 20 ml of 0.1 M citrate/NaOH, pH 2.7. The
unbound fractions, final washes, and neutralized eluates were analyzed
by SDS-PAGE under non-reducing conditions and Coomassie Blue
staining.
Mass Spectrometry—TRAIL in a matrix of sinapinic acid (Aldrich)
was analyzed in a matrix-assisted laser desorption ionization time-of-
flight mass spectrometer (Voyager-DE, Perspective Biosystem, Fram-
ingham, MA) equipped with a nitrogen laser (l 5 317 nm) to desorb and
ionize the sample. Ion masses were assigned based on an external mass
calibration using peptides of known molecular mass. Relative intensi-
ties in the matrix-assisted laser desorption ionization spectra are not
proportional to relative abundance of the species, due to intrinsic var-
iability in the desorption process.
Atomic Absorption—Proteins in 140 mM Suprapure NaCl were
loaded on a 5-ml HiTrap desalt column (Amersham Pharmacia Biotech)
equilibrated and eluted at 0.5 ml/min in 140 mM Suprapure NaCl.
Fractions (500 ml) were analyzed for protein content by the bicincho-
ninic acid assay (Pierce) using bovine serum albumin as a standard and
for zinc content by electrothermal atomization atomic absorption using
a Perkin-Elmer Analyst 800 spectrometer equipped with a graphite
furnace, using the external standard method and Zeemann background
correction. The light source was an Intensitron hollow cathode lamp
FIG. 1. Alignment of TNF family ligands and schematic representations showing the position of predicted disulfide bridges. A,
comparison of the extracellular protein sequences of TRAIL and other members of the TNF ligand family. Identical and homologous residues are
represented in black and shaded boxes, respectively. Cysteine residues are circled. The arrow points at the unpaired Cys230 residue of TRAIL.
Positions of b-strands are indicated above the sequence. B, some ligands of the TNF family have no disulfide bridge (class 1). Ligands with one
disulfide bridge fall into two classes. In class 2, the disulfide bridge links the CD loop with the EF loop (the location of the disulfide bridge in the
loop can vary). In class 3, a predicted disulfide bridge links b-sheet E with b-sheet F. TRAIL, the only member of class 4, resembles class 2 ligands
but lacks the Cys residue in the CD loop (replaced by a Glu residue). The unpaired Cys residues occurring in b-strands C, D, or F of some ligands
are not shown. LT, lyphotoxin.
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operated at 15 mA, using the 213.9 nm emission line for zinc. The
furnace temperature program was as follows: 30 s at 110 °C, 110–
130 °C over 15 s, 30 s at 130 °C, 130–300 °C over 15 s, 30 s at 300 °C,
5 s at 1800 °C (measure), and 3 s at 2450 °C (regeneration). The molar
ratio of zinc has been calculated using the following molecular masses:
23.8 (TRAIL), 24.2 (BAFF), and 37.5 kDa (thermolysin).
Dialysis and Proteolytic Assay—Purified wt TRAIL expressed in E.
coli (100 mg per condition) was dialyzed for 7 days at 4 °C against 1000
volumes of TBS, pH 7.5, supplemented or not with 1 mM EGTA, EDTA
or ortho-phenanthroline. Buffers were replaced after 24 h. Dialyzed
TRAILs were assayed for TRAIL-R2 binding and for zinc content as
described above. Thermolysin was dialyzed for 24 h under otherwise
identical conditions. Its proteolytic activity was measured as follows:
thermolysin (3 mg/ml) was incubated for 0, 5, 10, 20, and 30 min at 37 °C
in TBS containing 4 mg/ml azocasein (Sigma). Reactions were stopped
by the addition of an equal volume of ice-cold trichloroacetic acid at 5%.
After centrifugation, absorbance of supernatants containing soluble
azocasein peptides was measured at 366 nm.
RESULTS AND DISCUSSION
TRAIL Contains an Unpaired Cys Residue—Members of the
TNF family can be classified into three main classes on the
basis of the disulfide bridge pattern in their extracellular TNF
homology domains. LTa, LTb, 4–1BBL, and TRANCE have no
disulfide bridges. The crystal structures of TNFa and CD40L
reveal the presence of a disulfide bridge between the CD and
EF loops (8), and FasL, LIGHT, VEGI, CD30L, and CD27L
have a predicted disulfide bridge at corresponding positions.
Finally, TWEAK, EDA, APRIL, and BAFF have a predicted
disulfide bridge between b-strands E and F (Fig. 1). In addi-
tion, several ligands display unpaired Cys residues that are
mainly located in the middle of b-strands C (mLTa, LTb,
TWEAK, TRANCE, and CD30L), D (CD40L), or F (EDA).
TRAIL is unique in that both the human and murine sequences
contain a single Cys residue in the TNF homology domain that
is located in the EF loop at the exact same position as one of the
Cys of the disulfide bridge of TNFa, FasL, and LIGHT. How-
ever, the corresponding position in the CD loop of TRAIL is a
Glu residue instead of the expected Cys residue. As the role of
this unpaired Cys residue of TRAIL was unclear, we decided to
study its function in more detail.
FIG. 2. Cys230 is required for activity and pH stability of recombinant TRAIL expressed in bacteria. A, Coomassie Blue-stained gel
showing affinity purified recombinant soluble FLAG-TRAIL (wt and mutants) expressed in E. coli. B, cytotoxic activity of wt and mutated TRAILs.
Jurkat cells were incubated for 16 h in the presence of anti-FLAG antibody and of the indicated concentrations of recombinant TRAILs shown in
A. C, recombinant soluble TRAILs were analyzed by gel permeation chromatography and detected on line at 280 nm. The elution positions of
molecular mass markers (in kDa) are indicated at the top of the figure. The presence of FLAG-TRAIL in the main peaks was confirmed by Western
blotting (not shown). D, soluble extracts of bacteria expressing wt or C230A TRAIL were prepared at various pH values and were analyzed by
SDS-PAGE and Coomassie Blue staining. The band of overexpressed TRAIL is indicated. E, receptor binding ELISA for wt and C230A TRAILs.
TRAIL wt and C230A contained in crude bacterial extracts prepared at different pH values (see D) were allowed to bind in PBS to coated
TRAIL-R2:Fc or to the TNF-R1:Fc negative control. Values obtained for the negative control have been subtracted in the results presented.
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Cys230 of TRAIL Is Essential for TRAIL Activity and pH
Stability—Soluble forms of wild type (wt) and mutated (C230A
and C230S) FLAG-tagged recombinant soluble TRAILs were
produced in E. coli (Fig. 2A), and their activities were assayed
on the TRAIL-sensitive Jurkat cell line. TRAIL wt was cyto-
toxic when cross-linked with anti-FLAG antibodies, as de-
scribed previously (Fig. 2B) (15). In contrast, TRAILs C230A
and C230S were totally inactive under the same conditions
(Fig. 2B). The interaction between wt TRAIL and TRAIL-R1,
-R2, -R3, and -R4 was readily demonstrated in an ELISA,
whereas TRAILs C230A and C230S showed very little specific
binding and only at high concentrations (data not shown). The
integrity of the quaternary trimeric structure of TRAIL was
determined by gel permeation chromatography. We found that
wt TRAIL eluted from the column with an apparent mass of
about 80 kDa, which is compatible with a trimeric structure. In
contrast, TRAIL C230S and C230A were markedly smaller and
eluted with an apparent mass of about 28 kDa corresponding to
a monomer (Fig. 2C and data not shown). As the affinity puri-
fication procedure included an acid elution step, we assessed
acid lability of TRAIL. Bacteria expressing comparable levels of
wt or mutated TRAIL were lysed at different pH values (Fig.
2D), and TRAIL-R2 binding activity of these extracts was sub-
sequently measured in PBS (Fig. 2E). In bacterial lysates pre-
pared at pH 8 or pH 7, wt TRAIL bound TRAIL-R2 200–1000-
fold better than mutated TRAIL. In addition, a clear pH
sensitivity effect was observed for mutant, but not for wt
TRAIL, in lysates prepared at higher or lower pH values (Fig.
2E). Mutation of Cys230 therefore affects both the activity and
stability of TRAIL.
Full-length Membrane-bound C230A TRAIL Is Inactive in
Mammalian Cells—We confirmed the effect of Cys230 mutation
on TRAIL activity in a distinct experimental setup, using N-
terminally FLAG-tagged, full-length TRAIL expressed in mam-
malian cells. Whenever TRAIL was expressed in mammalian
cells, we only used the C230A mutation because the C230S
mutation generated a predicted N-glycosylation site in the
sequence of TRAIL, which was indeed utilized during biosyn-
thesis. Both wt and C230A TRAILs were expressed at compa-
rable levels (Fig. 3A), but only cells transfected with wt TRAIL
displayed significant cytotoxic activity on the target BJAB cells
(Fig. 3B). The observed cytotoxic activity was completely abro-
gated by soluble TRAIL-R2, but not by the soluble Fas control,
FIG. 3. Cys230 is required for the activity and trimerization of TRAIL expressed in mammalian cells. A, expression of full-length
TRAILs in 293T cells. 293T cells were transiently transfected with expression constructs for N-terminally FLAG-tagged full-length TRAIL (wt or
C230A), and cell extracts were analyzed under reducing conditions by Western blotting with anti-FLAG. B, Cys230 is required for the activity of
full-length TRAIL in mammalian cells. 293T cells were transfected with full-length TRAIL as described in A and incubated at the indicated ratio
with 51Cr-labeled BJAB cells, in the presence or in the absence of Fas:Fc or TRAIL-R2:Fc. Non-transfected 293T cells did not induce specific lysis
of target cells (not shown). C, 293T cells were transiently transfected with expression constructs for secreted soluble TRAILs as indicated.
FLAG-TRAILs in the cell supernatants were immunoprecipitated (IP) with anti-FLAG-agarose, and the presence of co-immunoprecipitating
HA-TRAILs was assessed by Western blotting (upper part). Expression of the various proteins in the cell supernatants is also shown (lower part).
FIG. 4. Interchain disulfide bond formation in TRAIL is de-
pendent on Cys230 and reduces the affinity of TRAIL for TRAIL-
R2. A, FLAG-tagged recombinant soluble TRAIL expressed in E. coli
was analyzed by mass spectrometry. Ions at 23,832, 11,919, and 7944
represent the single, double, and triple charged ions of TRAIL, respec-
tively. The ion at 47,699 corresponds to dimeric TRAIL. B, FLAG-
tagged recombinant soluble TRAIL expressed in E. coli was analyzed by
SDS-PAGE under reducing and non-reducing conditions and stained
with Coomassie Blue. DTT, dithiothreitol. Presence of the FLAG tag in
the 27- and 54-kDa bands was confirmed by Western blotting (not
shown). C, secreted FLAG-tagged soluble TRAIL expressed in 293T
cells was analyzed by SDS-PAGE under reducing or non-reducing con-
ditions and detected by Western blotting. D, FLAG-tagged recombinant
soluble TRAIL expressed in E. coli was immunoprecipitated with sub-
stoichiometric amounts of TRAIL-R2:Fc (or CD40:Fc as a control) and
protein A-Sepharose. Proteins in the unbound fraction (Unbound), the
last wash (Wash), and the eluate (Eluate) were analyzed by SDS-PAGE
under non-reducing conditions and revealed by Coomassie Blue stain-
ing. Molecular mass markers are in kDa.
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confirming that the observed cytotoxicity was a direct effect of
TRAIL expression. Thus, Cys230 is essential for TRAIL cytotox-
icity, regardless of the construct and expression system used.
A defect in the quaternary structure of TRAIL C230A was
observed in the mammalian expression system by co-immuno-
precipitation of secreted soluble TRAILs. Wild type TRAILs
expressed with two different tags co-precipitated, showing
their oligomerization capacity. In contrast, TRAIL C230A
failed to interact either with itself or with wt TRAIL (Fig. 3C).
We conclude that Cys230 plays an essential role in the assembly
and/or maintenance of the quaternary structure of TRAIL.
Formation of an Interchain Disulfide Bridge Decreases
TRAIL Activity—In proteins, cysteine residues can be involved
in posttranslational events such as internal thioester and di-
sulfide bridge formation, isoprenylation, fatty acid acylation,
and metal coordination, or they can remain as a free SH group
displaying a structural or catalytic role. The measured molec-
ular mass of TRAIL (23,832 6 10 Da, predicted 23,839.8 Da)
and its soluble behavior during Triton X-114 phase separation
excluded that Cys230 would carry large or hydrophobic sub-
stituents (Fig. 4A and data not shown). However, a minor
proportion of the recombinant TRAIL produced in E. coli mi-
grated as a dimer by SDS-PAGE under non-reducing condi-
tions, indicating the presence of an interchain disulfide bridge.
A minor species of 47,699 6 20 Da, corresponding to a TRAIL
dimer, was also detected by mass spectrometry (Fig. 4, A and
B). When TRAIL was expressed in mammalian cells, disulfide-
linked TRAIL was by far the major product (Fig. 4C), but
dimers were never detected in Cys230 mutants, indicating that
Cys230 is directly implicated in disulfide bridge formation. In
our hands, soluble TRAILs expressed in mammalian cells (with
high disulfide bridge content) have been consistently less
cytotoxic than those produced in E. coli (with low disulfide
bridge content), and we have measured a 20–30-fold lower
specific activity for their binding to TRAIL-R2. This may
indicate that disulfide-linked Cys230 is not favorable for TRAIL
activity. Indeed, we found that non-disulfide-linked TRAIL
bound recombinant receptor better than disulfide-linked
TRAIL (Fig. 4D).
Interestingly, both wt and C230A full-length TRAIL ex-
pressed in mammalian cells formed dithiothreitol-sensitive
dimers, which migrated with slightly different mobilities, rais-
ing the possibility that additional interchain disulfide bridges
may occur in the membrane proximal portion of the extracel-
lular domain of TRAIL, where 2 additional Cys residues are
located (data not shown). Whether this results in the cross-
linking of membrane-bound TRAIL trimers remains to be
determined.
Trimeric TRAIL Contains Stoichiometric Amounts of Zinc—
Cysteine residues are known to coordinate zinc atoms to pro-
teins, and as the Cys residues of TRAIL are suitably positioned
to coordinate a metal ion (10–12), we measured the zinc con-
tent in recombinant TRAIL by atomic absorption. Proteins
were prepared in a low zinc solution and size-fractionated just
prior to analysis to remove the ubiquitous unbound zinc ions.
We measured 1.08 mol of zinc per mol of positive control (the
zinc-metalloprotease thermolysin), 0.027 mol of zinc per mol of
negative control (BAFF, another TNF family member (13)), and
0.326 mol of zinc per mol of TRAIL, i.e. 0.98 mol of zinc per
TRAIL trimer, whereas TRAIL C230S only contained back-
ground levels of zinc (Fig. 5 and data not shown). Taken to-
gether, our data strongly suggest that the Cys230 residues
FIG. 5. Recombinant soluble TRAIL
contains a zinc atom. A, Coomassie
Blue staining of TRAIL and BAFF used in
C and D. Both ligands were expressed in
E. coli. Molecular mass markers are in
kDa. B, thermolysin was loaded onto a
HighTrap desalting column and eluted in
140 mM NaCl. Fractions were analyzed
for both protein (open squares) and zinc
contents (closed circles). C, TRAIL was
analyzed as described in B. The flow-
through of the last wash in Centrikon-30
(see “Materials and Methods”) was also
analyzed (BG zinc, open circles). D, as for
C, except that BAFF was analyzed.
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coordinate one zinc atom per trimeric TRAIL, therefore stabi-
lizing TRAIL in the correct conformation for receptor binding
and activity. Surprisingly, dialysis of TRAIL for as long as a
week against any of the chelating agents EGTA, EDTA, or
ortho-phenanthroline did not significantly alter its binding to
TRAIL-R2, whereas the proteolytic activity of the positive con-
trol thermolysin was completely abolished after only 1 day of
these treatments. Atomic absorption analysis indicated that
zinc was still present in dialyzed TRAIL, suggesting that zinc is
tightly associated with TRAIL and/or not accessible within the
structure (data not shown). However, we cannot exclude that
different experimental conditions may achieve zinc removal
from TRAIL, as published recently (16).
Our results are strongly supported by the crystallographic
study of Hymowitz et al. (11), which shows that a tetrahedral
zinc atom is coordinated to Cys230 of the three TRAIL mono-
mers and to an interior chloride ion. No zinc atoms were re-
ported in the other two available structures (10, 12), but it is
noteworthy that in both cases TRAIL was obtained by refolding
from inclusion bodies, which may preclude uptake of a zinc
atom. In one case, an S–S bridge occurred between two Cys230
of TRAIL co-crystallized with TRAIL-R2 (12). Although disul-
fide-linked TRAIL binds to its receptor less efficiently than
zinc-containing TRAIL (Fig. 4D), it is conceivable that it may
play a physiological role under certain conditions. TRAIL with
a C230S mutation has been described as being indistinguish-
able from wt TRAIL in its ability to immunoprecipitate
TRAIL-R2 (12), which is in discrepancy with our results. How-
ever, immunoprecipitation may not reveal a change in affinity,
especially if one of the components is present in large excess. It
is also possible that refolded wt TRAIL lacking the zinc atom
may display the same decreased activity as the Cys230 mutant.
In addition to TRAIL, several TNF family members display
unpaired Cys residues in their receptor-binding domain. The
Cys residue present in the b-sheet C of TWEAK, LTb, and
CD30L corresponds to and probably fulfills the same structural
role as Ser186 of TRAIL, which faces to the interior of the
monomer and is engaged in a hydrogen bond with the backbone
oxygen of Phe274 in b-sheet H. Cys194 of CD40L in b-sheet D is
located on the outer surface of the trimer (9) and is not con-
served in murine CD40L. Finally, the unpaired Cys residues of
EDA and TRANCE are predicted to be distant in the trimeric
structure based on sequence alignment with TNF family mem-
bers of known structures (Fig. 1A). The metalloprotein TRAIL
thus remains unique within the TNF family. Comparison of the
primary and three-dimensional structure of TNFa (8) and
TRAIL (11, 12) shows that both ligands have very good overall
structural homology, except in the three following loops: AA9
(which is exceptionally long in TRAIL), CD, and EF. In TNFa,
loops CD and EF are linked by a disulfide bridge (see Fig. 1B),
whereas loop EF of TRAIL is arranged differently to allow
correct positioning of the unpaired Cys residue to chelate a zinc
atom.
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